158 related articles for article (PubMed ID: 32524923)
21. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.
Clement FM; Harris A; Li JJ; Yong K; Lee KM; Manns BJ
JAMA; 2009 Oct; 302(13):1437-43. PubMed ID: 19809025
[TBL] [Abstract][Full Text] [Related]
22. Medicine reimbursement recommendations in Canada, Australia, and Scotland.
Lexchin J; Mintzes B
Am J Manag Care; 2008 Sep; 14(9):581-8. PubMed ID: 18778173
[TBL] [Abstract][Full Text] [Related]
23. Health Technology Assessment in Australia: The Pharmaceutical Benefits Advisory Committee and Medical Services Advisory Committee.
Kim H; Byrnes J; Goodall S;
Value Health Reg Issues; 2021 May; 24():6-11. PubMed ID: 33429153
[TBL] [Abstract][Full Text] [Related]
24. Analysis of consumer comments into PBAC decision-making (2014-9).
Tjeuw E; Wonder MJ
Int J Technol Assess Health Care; 2022 Feb; 38(1):e18. PubMed ID: 35115073
[TBL] [Abstract][Full Text] [Related]
25. The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004.
Harris AH; Hill SR; Chin G; Li JJ; Walkom E
Med Decis Making; 2008; 28(5):713-22. PubMed ID: 18378939
[TBL] [Abstract][Full Text] [Related]
26. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme.
Robertson J; Walkom EJ; Henry DA
Aust Health Rev; 2009 May; 33(2):192-9. PubMed ID: 19563308
[TBL] [Abstract][Full Text] [Related]
27. Governments Need Better Guidance to Maximise Value for Money: The Case of Australia's Pharmaceutical Benefits Advisory Committee.
Carter D; Vogan A; Haji Ali Afzali H
Appl Health Econ Health Policy; 2016 Aug; 14(4):401-407. PubMed ID: 26818196
[TBL] [Abstract][Full Text] [Related]
28. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
Henry D
Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
[TBL] [Abstract][Full Text] [Related]
29. Towards a Transparent, Credible, Evidence-Based Decision-Making Process of New Drug Listing on the Hong Kong Hospital Authority Drug Formulary: Challenges and Suggestions.
Wong CKH; Wu O; Cheung BMY
Appl Health Econ Health Policy; 2018 Feb; 16(1):5-14. PubMed ID: 28702874
[TBL] [Abstract][Full Text] [Related]
30. Same drugs, valued differently? Comparing comparators and methods used in reimbursement recommendations in Australia, Canada, and Korea.
Bae G; Bae EY; Bae S
Health Policy; 2015 May; 119(5):577-87. PubMed ID: 25666339
[TBL] [Abstract][Full Text] [Related]
31. How Data Packages Lacking Phase III Pivotal Trial Data Can Support Regulatory Approval and Reimbursement for Oncologics in Australia.
Macaulay R; Siddiqui MK; Stoddart S
Value Health Reg Issues; 2015 May; 6():143-149. PubMed ID: 29698188
[TBL] [Abstract][Full Text] [Related]
32. A systematic review of economic evaluations in second and later lines of therapy for the treatment of non-small cell lung cancer.
Jäkel A; Plested M; Dharamshi K; Modha R; Bridge S; Johns A
Appl Health Econ Health Policy; 2013 Feb; 11(1):27-43. PubMed ID: 23329379
[TBL] [Abstract][Full Text] [Related]
33. Exploring the implications of a fixed budget for new medicines: a study of reimbursement of new medicines in Australia and New Zealand.
Taylor C; Wonder M
Aust Health Rev; 2015 Sep; 39(4):455-461. PubMed ID: 25751688
[TBL] [Abstract][Full Text] [Related]
34. A will and a way to fund medicines for rare diseases: the story of human growth hormone replacement for adults with growth hormone deficiency.
Lipworth W; Ambler G; Burt MG; Fairchild J; Inder WJ; Werther G; Ho K
Intern Med J; 2018 Aug; 48(8):999-1002. PubMed ID: 30133980
[TBL] [Abstract][Full Text] [Related]
35. How are Child-Specific Utility Instruments Used in Decision Making in Australia? A Review of Pharmaceutical Benefits Advisory Committee Public Summary Documents.
Bailey C; Dalziel K; Cronin P; Devlin N; Viney R;
Pharmacoeconomics; 2022 Feb; 40(2):157-182. PubMed ID: 34738210
[TBL] [Abstract][Full Text] [Related]
36. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
37. Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand.
McCormick JI; Berescu LD; Tadros N
Orphanet J Rare Dis; 2018 Jan; 13(1):27. PubMed ID: 29382371
[TBL] [Abstract][Full Text] [Related]
38. Will the Australia-United States Free Trade Agreement undermine the Pharmaceutical Benefits Scheme?
Harvey KJ; Faunce TA; Lokuge B; Drahos P
Med J Aust; 2004 Sep; 181(5):256-9. PubMed ID: 15347273
[TBL] [Abstract][Full Text] [Related]
39. Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.
Main C; Bojke L; Griffin S; Norman G; Barbieri M; Mather L; Stark D; Palmer S; Riemsma R
Health Technol Assess; 2006 Mar; 10(9):1-132. iii-iv. PubMed ID: 16545208
[TBL] [Abstract][Full Text] [Related]
40. Assessing the safety and cost-effectiveness of early nanodrugs.
Vines T; Faunce T
J Law Med; 2009 May; 16(5):822-45. PubMed ID: 19554862
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
